<DOC>
	<DOCNO>NCT00243867</DOCNO>
	<brief_summary>The primary objective trial compare survival patient advance non-small cell lung cancer ( NSCLC ) treat weekly Taxoprexin combination carboplatin treat paclitaxel plus carboplatin prospectively randomize trial . In addition , response rate regimen , response duration , time progression time treatment failure measure . Toxicity evaluate compare two group .</brief_summary>
	<brief_title>Taxoprexin Plus Carboplatin Treatment Advanced Lung Cancer</brief_title>
	<detailed_description>This randomize , multicenter , Phase III open-label study weekly Taxoprexin速 combination every three ( 3 ) week carboplatin compare paclitaxel plus carboplatin every three ( 3 ) week , patient advance non-small cell lung cancer ( NSCLC ) receive cytotoxic agent advanced disease . Patients may previously treat immunological agent . Patients randomize receive Taxoprexin速 dose 400 mg/m2 intravenously one ( 1 ) -hour weekly infusion , 5/6 week follow immediately carboplatin AUC = 4 week one ( 1 ) four ( 4 ) 30 minute intravenous infusion paclitaxel 225mg/m2 three ( 3 ) hour intravenous infusion follow immediately carboplatin AUC = 6 30 minute intravenous infusion , every three ( 3 ) week . Patients receive Taxoprexin速 carboplatin infusion paclitaxel carboplatin infusion progression disease , intolerable toxicity , completion six ( 6 ) treatment cycle paclitaxel plus carboplatin three ( 3 ) treatment cycle Taxoprexin速 plus carboplatin , refusal continue treatment patient , Investigator decision .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologic cytologic diagnosis nonsmall cell lung cancer . At time study entry , patient must locally advance ( stage IIIb ) metastatic ( stage IV ) disease . 2 . Patients must least one site either measurable nonmeasurable disease . 3 . Patients must receive prior systemic chemotherapy metastatic disease . Prior adjuvant systemic chemotherapy allow . At least six ( 6 ) month must elapse since prior adjuvant systemic chemotherapy . 4 . At least 6 week ( 42 day ) since prior immunotherapy , cytokine , biologic , vaccine non chemotherapy anticancer systemic therapy , unless patient progressed therapy . 5 . At least 4 week ( 28 day ) since prior radiotherapy &gt; 25 % bone marrow . 6 . Patients must ECOG performance status 0 2 . 7 . Patients must least 18 year age . 8 . Patients must adequate hepatic renal function . 9 . Patients must adequate bone marrow function . 10 . Life expectancy least 3 month . 11 . Patients must sign informed consent form indicate aware investigational nature study keep policy institution . 1 . Patients receive prior systemic chemotherapy adjuvant set treatmentfree interval less six ( 6 ) month . 2 . Patients past current history neoplasms entry diagnosis , except curatively treat nonmelanoma skin cancer carcinoma situ cervix except cancer treated cure diseasefree survival great 5 year . 3 . Patients symptomatic brain metastasis ( e ) . 4 . Women pregnant nurse men woman practice acceptable method birth control . Women may breastfeed study . 5 . Patients current active infection require antiinfectious treatment ( e.g. , antibiotic , antiviral , antifungal ) . 6 . Patients current peripheral neuropathy etiology great grade 1 . 7 . Patients unstable serious concurrent medical condition . 8 . Patients know hypersensitivity Cremophor . 9 . Patients Gilbert 's syndrome . 10 . Patients must major surgery within past 14 day . 11 . Patients must receive concurrent chemotherapy , radiotherapy , immunotherapy study . 12 . No known HIV disease infection . 13 . Patients receive ketoconazole , erythromycin , verapamil , diazepam , quinidine , diltiazem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
</DOC>